Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.56 |
| ▸ | PPARA | Q07869 | 9/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10944842 | 0.77 | PPARG (0.51) | PPARGPPARALDHAACECA2 | |
| SCHEMBL10944848 | 0.77 | PPARG (0.51) | PPARGPPARALDHAACECA2 | |
| SCHEMBL21043375 | 0.76 | CA1 (0.52) | PPARGPPARAITGB3ITGA2BLDHA | |
| SCHEMBL7870056 | 0.74 | PPARG (0.57) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL7403870 | 0.74 | PPARG (0.46) | PPARGPPARAPPARDKLK5ACE | |
| SCHEMBL7408782 | 0.74 | PPARG (0.46) | PPARGPPARAPPARDKLK5ACE | |
| SCHEMBL7403869 | 0.74 | PPARG (0.46) | PPARGPPARAPPARDKLK5ACE | |
| SCHEMBL5374891 | 0.74 | ACE (0.61) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL7390262 | 0.74 | ACE (0.61) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL335310 | 0.74 | ITGB3 (0.67) | PPARGPPARAITGB3ITGA2BLDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205435-B2 | Type B botulism toxin inhibitors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2007-04-17 | — | — | US | disclosed |
| US-20040176333-A1 | Type b botulism toxin inhibitors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176333-A1 | Type b botulism toxin inhibitors | GZMB, CFB, MAOB | PPARG 4878/4885PPARA 4867/4885PPARD 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.